Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India
· Delayed Price · Currency is INR | Market Cap | 1.13T |
| Revenue (ttm) | 345.83B |
| Net Income (ttm) | 56.59B |
| Shares Out | n/a |
| EPS (ttm) | 67.93 |
| PE Ratio | 19.93 |
| Forward PE | 23.91 |
| Dividend | 8.00 (0.66%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 2,336,111 |
| Average Volume | 3,079,827 |
| Open | 1,342.40 |
| Previous Close | 1,334.50 |
| Day's Range | 1,327.40 - 1,367.90 |
| 52-Week Range | 1,129.40 - 1,379.70 |
| Beta | 0.30 |
| RSI | 66.78 |
| Earnings Date | May 12, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In fiscal year 2025, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026
Dr. Reddy's Laboratories Ltd. is set to release its financial results for the fourth quarter and full year ending March 31, 2026, on Tuesday, May 12, 2026. The announcement will…
Why are Dr Reddy’s shares falling nearly 2% today? Explained
Shares of Dr Reddy’s Laboratories fell on Friday, April 24, after global brokerage Goldman Sachs downgraded the stock to ‘Sell’ from ‘Neutral’ and cut its target price to Rs 1,075,…
Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup
A busy morning for broker calls with Infosys drawing the most divided analyst opinion after its Q4 FY26 results, Dr Reddy's receiving back-to-back downgrades on the Semaglutide opportunity, Cipla gett...
A Look at Dr Reddy's Laboratories Ltd (RDY) After 5.8% Gain -- GF Value $15.06 vs Price $13.58
A Look at Dr Reddy's Laboratories Ltd (RDY) After 5.8% Gain -- GF Value $15.06 vs Price $13.58
Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs
Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs
Dr. Reddy's (RDY) Shares Surge on Generic Drug News
Dr. Reddy's (RDY) Shares Surge on Generic Drug News
Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more
Indian equity benchmarks ended lower on Thursday, April 23, 2026, with the NIFTY 50 closing at 24,173.05, down 205.05 points (-0.84%). Despite the broader market weakness, select stocks managed to…
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Dr. Reddy's Laboratories shares surge 7% today, April 23: Details here
Shares of Dr. Reddy's Laboratories Limited rose over 7% on Thursday, April 23, trading against the broader market trend during the session. The stock opened at ₹1,230.00 against its previous…
Nifty 50 top losers today, April 21: SBI Life, Bharat Electronics, Dr. Reddy's Laboratories, Jio Financial Services and more
India’s benchmark indices ended higher on April 21, but a few heavyweights in the Nifty 50 closed in the red, reflecting selective profit booking across sectors. The Nifty 50 settled…
Torrent Pharma, Dr. Reddy’s and Zydus Life benefit as generic Semaglutide market share rises to 33% within 10 days of launch
The launch of generic Semaglutide in India has made an immediate and dramatic impact on the obesity and diabetes drug market, with CLSA’s latest healthcare channel check note revealing a…
Dr Reddy's board to consider final dividend for FY 2025-26
Dr Reddy's Laboratories will hold a board meeting to consider recommending a final dividend for the financial year 2025-26, the company disclosed in a regulatory filing on 16 April 2026.…
Pharma sector stocks surge today, April 15: Indoco Remedies up 5%, Orchid Pharma gains 4.04%, Dr. Reddy's falls 1.64%
Indian pharmaceutical sector stocks traded higher in early morning trade on Tuesday, April 15, 2026, with most counters advancing while Dr. Reddy's Laboratories remained an outlier on the downside. Am...
Dr. Reddy's Laboratories sells Svaas Wellness for Rs 2.23 crore
Dr. Reddy's Laboratories has announced the sale of its wholly owned subsidiary, Svaas Wellness Limited, for a total consideration of ₹2.23 crore. The agreement for the sale was finalised on…
Nifty 50 top losers today, April 7: Dr. Reddy's Laboratories, IndiGo, Adani Enterprises, Apollo Hospitals and more
Indian equity benchmarks closed higher on April 7, 2026, despite a volatile trading session, with the Nifty 50 ending above the 23,100 mark. However, selective profit booking was visible across…
Top gainers among Nifty 50 stocks in midday trades today, April 2: HCL Technologies up 1.1%, Dr. Reddy's Lab up 0.3%
IT stocks emerged as the top gainers among Nifty 50 constituents in midday trade on April 2, even as broader indices continued to trade lower during the session. As of…
Dr. Reddy's Laboratories issues 3,675 equity shares under ESOPs
Dr. Reddy's Laboratories has allotted 3,675 equity shares to eligible employees following the exercise of stock options under its Employees ADR Stock Options Scheme, 2007. The allotment took place on…
Dr Reddy's Laboratories Ltd (RDY) Trading 3.12% Higher on Mar 25
Dr Reddy's Laboratories Ltd (RDY) Trading 3.12% Higher on Mar 25
Setback for Dr Reddy’s as Delhi High Court asks company to halt Olympiq drug sales
The Delhi High Court today, March 25 directed Dr. Reddy’s Laboratories to immediately halt further sales and market expansion of its semaglutide-based diabetes drug under the brand name Olymviq Justic...
Dr. Reddy's Laboratories updates code for fair disclosure of price-sensitive information
Dr. Reddy's Laboratories has announced an update to its 'Code of Practices and Procedures for Fair Disclosures of Un-published Price Sensitive Information'. This update aligns with the Securities and ...
Domestic companies launch semaglutide jabs at affordable prices
Indian pharmaceutical giants like Sun Pharma, Torrent, and Dr. Reddy's have launched affordable semaglutide, a groundbreaking weight-loss drug, following Novo Nordisk's patent expiry. This move signif...
Dr. Reddy's Laboratories launches India's first DCGI-approved semaglutide injection
Dr. Reddy’s Laboratories has announced the launch of Obeda®, India’s first DCGI-approved semaglutide injection for Type 2 Diabetes. This launch marks Dr. Reddy’s Day-1 entry into the GLP-1 receptor ag...
Dr. Reddy's Laboratories updates on Eftilagimod Alfa trial discontinuation
Dr. Reddy's Laboratories has announced that Immutep's Independent Data Monitoring Committee recommended halting the TACTI-004 Phase III trial of Eftilagimod Alfa for non-small cell lung cancer. This d...
Dr. Reddy's Laboratories issues 10,275 equity shares under stock options scheme
Dr. Reddy's Laboratories has allotted 10,275 equity shares to eligible employees following the exercise of stock options under its employee stock option schemes. The shares, with a par value of…
What is dragging Dr Reddy’s shares 2% down today? Explained
Shares of Dr Reddy's Laboratories declined in early trade on Monday, March 9, as broader market weakness weighed on investor sentiment. As of 9:54 AM, the stock was trading at…